Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)

T. Meniawy, G. Richardson, A. Townsend, J. Desai, Hui K. Gan, Michael Friedlander, L. Horvath, M. B. Jameson, S. Sandhu, Z. Wu, Z. Qin, K. Kang, B. Markman

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume28
Publication statusPublished - Sep 2017
Externally publishedYes
Event42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain
Duration: 8 Sep 201712 Sep 2017

Cite this

Meniawy, T., Richardson, G., Townsend, A., Desai, J., Gan, H. K., Friedlander, M., Horvath, L., Jameson, M. B., Sandhu, S., Wu, Z., Qin, Z., Kang, K., & Markman, B. (2017). Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). Annals of Oncology, 28.